{"title":"外阴佩吉特病的生存和治疗模式:来自SEER的证据。","authors":"Lele Chang, Yaxin Kang, Jing Liu, Cuibo Lin, Qin Xu","doi":"10.1177/10732748261450261","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionVulvar Paget's disease (VPD) is a rare condition, and a comprehensive analysis of its clinical and pathological characteristics, treatment approaches, and prognosis has not yet been conducted.MethodsWe conducted a retrospective population-based cohort study using publicly available, de-identified data from the Surveillance, Epidemiology, and End Results (SEER) database. Patients diagnosed with VPD between 2004 and 2021were included. Kaplan-Meier and Cox models assessed impacts on overall and cancer-specific survival. Propensity score matching (PSM) balanced surgical and non-surgical groups.Results1,778 patients with VPD were included. Most patients were women aged ≥50 years (96.5%) and of White race (81.7%). The labium majus was the most commonly specified tumor site (203/1,778, 11.4%), although most cases were recorded as vulva, NOS. A total of 1,374 patients underwent surgical treatment. After PSM, surgery remained associated with improved survival. A generally similar trend was observed across subgroups, although not all subgroup comparisons reached statistical significance.ConclusionBased on the SEER database, this study found that surgery was beneficial for improving the prognosis of VPD patients, especially for those who were elderly.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261450261"},"PeriodicalIF":3.1000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13180072/pdf/","citationCount":"0","resultStr":"{\"title\":\"Survival and Treatment Patterns in Vulvar Paget's Disease: Evidence From SEER.\",\"authors\":\"Lele Chang, Yaxin Kang, Jing Liu, Cuibo Lin, Qin Xu\",\"doi\":\"10.1177/10732748261450261\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>IntroductionVulvar Paget's disease (VPD) is a rare condition, and a comprehensive analysis of its clinical and pathological characteristics, treatment approaches, and prognosis has not yet been conducted.MethodsWe conducted a retrospective population-based cohort study using publicly available, de-identified data from the Surveillance, Epidemiology, and End Results (SEER) database. Patients diagnosed with VPD between 2004 and 2021were included. Kaplan-Meier and Cox models assessed impacts on overall and cancer-specific survival. Propensity score matching (PSM) balanced surgical and non-surgical groups.Results1,778 patients with VPD were included. Most patients were women aged ≥50 years (96.5%) and of White race (81.7%). The labium majus was the most commonly specified tumor site (203/1,778, 11.4%), although most cases were recorded as vulva, NOS. A total of 1,374 patients underwent surgical treatment. After PSM, surgery remained associated with improved survival. A generally similar trend was observed across subgroups, although not all subgroup comparisons reached statistical significance.ConclusionBased on the SEER database, this study found that surgery was beneficial for improving the prognosis of VPD patients, especially for those who were elderly.</p>\",\"PeriodicalId\":49093,\"journal\":{\"name\":\"Cancer Control\",\"volume\":\"33 \",\"pages\":\"10732748261450261\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2026-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13180072/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Control\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10732748261450261\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/5/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10732748261450261","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Survival and Treatment Patterns in Vulvar Paget's Disease: Evidence From SEER.
IntroductionVulvar Paget's disease (VPD) is a rare condition, and a comprehensive analysis of its clinical and pathological characteristics, treatment approaches, and prognosis has not yet been conducted.MethodsWe conducted a retrospective population-based cohort study using publicly available, de-identified data from the Surveillance, Epidemiology, and End Results (SEER) database. Patients diagnosed with VPD between 2004 and 2021were included. Kaplan-Meier and Cox models assessed impacts on overall and cancer-specific survival. Propensity score matching (PSM) balanced surgical and non-surgical groups.Results1,778 patients with VPD were included. Most patients were women aged ≥50 years (96.5%) and of White race (81.7%). The labium majus was the most commonly specified tumor site (203/1,778, 11.4%), although most cases were recorded as vulva, NOS. A total of 1,374 patients underwent surgical treatment. After PSM, surgery remained associated with improved survival. A generally similar trend was observed across subgroups, although not all subgroup comparisons reached statistical significance.ConclusionBased on the SEER database, this study found that surgery was beneficial for improving the prognosis of VPD patients, especially for those who were elderly.
期刊介绍:
Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.